Pancreatic Cancer Research

Clinical trialEarly Phase 1Withdrawn

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies

Outcome
Stopped earlyStudy held. (Other)
Phase
Early Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
December 2025
Planned end
November 2027
Enrollment
0 participants
Sites
0
Primary outcomes
MTD of the dose of MPT0B640
Sponsor type
Industry
Results posted
No
Last update
6 March 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center clinical trials. Open label. To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640

Detailed description public domain (ClinicalTrials.gov)

Classical 3+3 design to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 . Up to 9 times of administration, Oral suspension, once every 3rd day.